Orchard to orchestrate $173m IPO
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
Sutro seals $86m IPO
Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.
Principia achieves $122m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
Asarina diagnoses listing
Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
Allogene calls for $100m IPO
The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.
Sutro starts IPO proceedings
A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
Ascentage approaches Hong Kong IPO
Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.
Principia Biopharma primes $86m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.

Other News

Sensyne Health senses $76m IPO
Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.
Allakos accomplishes $128m IPO
The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.
Constellation consummates $60m IPO
The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.
MeiraGTx goes public for $75m
UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.
Akasol plugs into public markets
Forty Seven fetches $112m in IPO
The cancer drug developer and Stanford spinout floated at the top of its range in an offering that could reach $129m.

Editor's Picks

Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg


Not yet subscribed?

See your subscription offers here